Complementary dual mechanism: Empagliflozin promotes urinary glucose excretion by inhibiting SGLT‑2 in the kidneys, while linagliptin enhances incretin hormone levels (GLP‑1, GIP), stimulating insulin release and suppressing glucagon—offering synergistic glucose-lowering effects. 

Once‑daily, single-tablet convenience: Simplifies diabetes management with morning dosing, taken with or without food. 

Improved glycaemic control: Empagliflozin provides weight loss and blood pressure benefits, while linagliptin maintains insulin balance with a low risk of hypoglycemia. 

Cardio‑renal protection: Empagliflozin has demonstrated benefits in reducing cardiovascular death and slowing renal function decline in type 2 diabetics with established CVD. 

Locally accessible pricing: Each tablet is priced around ৳ 35 (strip of 10 cost ৳ 350), making it a competitive and affordable choice.